{"gene":"TFAP2B","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1997,"finding":"AP-2beta knockout mice die postnatally due to polycystic kidney disease caused by massive apoptotic death of collecting duct and distal tubular epithelia; in these mice, bcl-XL, bcl-w, and bcl-2 expression is down-regulated, and transfection of AP-2 into cell lines in vitro strongly suppresses c-myc-induced apoptosis, indicating AP-2beta programs cell survival during embryogenesis.","method":"Knockout mouse (loss-of-function), in vitro transfection assay, histological/molecular analysis of kidney development","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with defined cellular phenotype, supported by in vitro transfection assay showing suppression of c-myc-induced apoptosis, replicated across multiple analyses in one rigorous study","pmids":["9271117"],"is_preprint":false},{"year":2000,"finding":"Missense mutations in TFAP2B cause Char syndrome; mutant TFAP2B proteins dimerize normally in vitro but show abnormal binding to TFAP2 target sequences, and dimerization of mutants with normal TFAP2B adversely affects transactivation, demonstrating a dominant-negative mechanism for disease pathogenesis.","method":"In vitro dimerization assay, DNA-binding assay, transactivation assay in eukaryotic cells, positional candidacy mapping","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal functional assays (dimerization, DNA binding, transactivation) in a single rigorous study establishing dominant-negative mechanism","pmids":["10802654"],"is_preprint":false},{"year":2001,"finding":"Four additional TFAP2B mutations cause Char syndrome: two basic-domain mutations (R225C, R225S) abolish DNA binding in vitro; a transactivation-domain PY-motif mutation (P62R) retains DNA binding but shows dominant-negative effects in eukaryotic cells. All four mutants demonstrate dominant-negative effects, consistently implicating this mechanism in Char syndrome etiology.","method":"In vitro DNA-binding assay, transactivation assay in eukaryotic cells, mutation analysis","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple mutants analyzed with orthogonal methods (DNA binding + transactivation), replicating and extending the dominant-negative mechanism established in prior work","pmids":["11505339"],"is_preprint":false},{"year":2005,"finding":"Two intronic TFAP2B mutations in Char syndrome families cause aberrant splicing (demonstrated by biochemical studies in mammalian cells), producing frameshift mRNAs subject to nonsense-mediated decay, establishing haploinsufficiency as an alternative mechanism (distinct from dominant-negative) for TFAP2B-associated disease.","method":"Biochemical splicing assay in mammalian cells, sequencing, linkage analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical splicing assay plus genetic linkage, single lab, two methods","pmids":["15684060"],"is_preprint":false},{"year":2006,"finding":"GAS41 physically interacts with AP-2beta both in vivo (co-immunoprecipitation) and in vitro (GST pull-down); the two proteins co-localize in the nucleus; interaction maps to C-termini of both proteins; GAS41 stimulates AP-2beta transcriptional activity and enhances its DNA-binding activity as shown by EMSA.","method":"Co-immunoprecipitation, GST pull-down, co-localization (nuclear), EMSA, reporter transactivation assay, domain mapping","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP plus in vitro GST pull-down plus EMSA plus functional reporter assay, single lab but multiple orthogonal methods","pmids":["16698963"],"is_preprint":false},{"year":2007,"finding":"TFAP2B is a direct transcriptional target of the PAX3/FKHR fusion oncogene in alveolar rhabdomyosarcoma and mediates the anti-apoptotic (survival) function of PAX3/FKHR in these tumor cells, as validated by comparative expression profiling of PAX3/FKHR silencing in vitro and PAX3/FKHR-specific signatures in vivo.","method":"siRNA-mediated silencing, comparative expression profiling (in vitro and in vivo), functional anti-apoptosis validation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function (siRNA) with defined cellular phenotype (apoptosis) and cross-validated by in vivo expression signatures, single lab","pmids":["17525748"],"is_preprint":false},{"year":2008,"finding":"AP-2beta represses D1A dopamine receptor gene transcription via a specific silencer element (D1AS1) in D1A-negative Neuro2a cells; AP-2beta binds the D1AS1 site (shown by gel supershift with anti-AP-2beta antibody); co-transfection of AP-2beta expression vector represses D1A promoter activity in a D1AS1-dependent manner; decoy oligonucleotides de-repress the promoter.","method":"Deletion CAT reporter analysis, gel-shift/supershift assay, co-transfection, decoy oligonucleotide experiment, RT-PCR","journal":"Brain research. Molecular brain research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (gel shift, reporter, decoy oligo) in single lab establishing direct transcriptional repression mechanism","pmids":["10640692"],"is_preprint":false},{"year":1999,"finding":"In the developing chick retina, AP-2beta (expressed in amacrine and horizontal cells) represses the R-FABP promoter; cotransfection of AP-2 expression vectors with a CAT reporter construct in primary retinal cultures decreased R-FABP-dependent expression; R-FABP mRNA and AP-2beta show mutually exclusive expression patterns.","method":"cDNA cloning, in situ hybridization, co-transfection reporter assay in primary retinal cultures, mutational analysis of AP-2 binding site","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct reporter assay plus in vivo expression pattern, single lab, two orthogonal methods","pmids":["10090146"],"is_preprint":false},{"year":2008,"finding":"AP-2beta is required for noradrenaline (NA) neurotransmitter phenotype specification in both peripheral sympathetic ganglia and locus coeruleus; AP-2beta null mice show significantly reduced NA and dopamine beta-hydroxylase levels; pharmacological rescue with NA intermediate during pregnancy significantly rescues neonatal lethality of AP-2beta(-/-) mice, indicating NA deficiency is a main cause of lethality; forced expression of AP-2beta (but not other AP-2 factors) in neural crest stem cells favors their differentiation into NA neurons.","method":"Knockout mouse, neurochemical assay (NA/DBH measurement), pharmacological rescue experiment, forced expression in neural crest stem cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO with defined biochemical phenotype, pharmacological rescue establishing causal link, gain-of-function specificity experiment, multiple orthogonal approaches","pmids":["18424435"],"is_preprint":false},{"year":2010,"finding":"AP-2beta is required for the epinephrine neurotransmitter phenotype and maturation of adrenal chromaffin cells; AP-2beta(-/-) mice show reduced DBH and PNMT expression and >80% reduction in adrenal epinephrine; ultrastructural analysis reveals defective large secretory vesicle formation; ChIP assay of rat adrenal gland shows AP-2beta directly binds the PNMT gene upstream promoter in vivo.","method":"Knockout mouse, immunohistochemistry, neurochemical assay (EPI/catecholamine measurement), ultrastructural analysis (EM), chromatin immunoprecipitation (ChIP)","journal":"Molecular and cellular neurosciences","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — KO with defined biochemical phenotype, ChIP establishing direct promoter binding in vivo, ultrastructural validation, multiple orthogonal methods","pmids":["20875861"],"is_preprint":false},{"year":2011,"finding":"Tfap2b is expressed throughout ductus arteriosus development; Tfap2b knockout mice fail to close the ductus arteriosus after birth; Tfap2b directly controls Bmp2 and Bmp4 promoter activity (shown by gel-shift assay and reporter assays); loss of Tfap2b alters Bmp2 and Bmp4 expression in limb buds, causing postaxial accessory digits.","method":"Knockout mouse, in situ hybridization, histological analysis, gel-shift assay, promoter-reporter transfection assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — KO with two defined phenotypes (PDA, limb), gel shift and reporter assay establishing direct transcriptional regulation of Bmp2/Bmp4, multiple orthogonal methods","pmids":["21829553"],"is_preprint":false},{"year":2011,"finding":"AP-2beta and AP-2alpha are required for survival of sympathetic progenitors and differentiated noradrenergic neurons; AP-2beta knockout alone reduces sympathetic ganglion size ~40% via apoptotic death of neural crest progenitors and causes complete absence of locus coeruleus noradrenergic neurons; conditional double knockout of AP-2alpha/AP-2beta in sympathetic progenitors leads to near-complete loss of neurons postnatally.","method":"Constitutive and conditional knockout mice, histological/TUNEL analysis, conditional double KO with Cre-lox","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (constitutive and conditional KO) with defined apoptotic cellular phenotype, replicated across cell types","pmids":["21539825"],"is_preprint":false},{"year":2005,"finding":"AP-2beta overexpression in 3T3-L1 adipocytes causes cell enlargement, triglyceride accumulation, and enhanced glucose uptake via PLC and atypical PKCzeta/lambda (but not PI3-K) signaling; AP-2beta also activates Gab1 tyrosine phosphorylation and its association with PLCgamma; AP-2beta overexpression impairs insulin signaling; siRNA knockdown of AP-2beta inhibits glucose uptake.","method":"Overexpression and siRNA knockdown in 3T3-L1 adipocytes, pharmacological inhibitor experiments, kinase activity assays, co-immunoprecipitation","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with defined cellular phenotype, pathway dissection with inhibitors, single lab","pmids":["16373417"],"is_preprint":false},{"year":2010,"finding":"AP-2beta directly inhibits leptin expression in 3T3-L1 adipocytes by binding to the leptin promoter; overexpression decreases leptin promoter activity, mRNA, and protein secretion; knockdown increases leptin expression; EMSA and ChIP confirm specific AP-2beta binding to the leptin promoter (position +34 to +42 relative to TSS); site-directed mutagenesis of this AP-2 binding site abolishes the inhibitory effect.","method":"Overexpression, siRNA knockdown, promoter-reporter assay, EMSA, ChIP, site-directed mutagenesis","journal":"International journal of obesity","confidence":"High","confidence_rationale":"Tier 1 / Moderate — multiple orthogonal methods including mutagenesis of binding site, ChIP, EMSA, and gain/loss-of-function, single lab","pmids":["20065963"],"is_preprint":false},{"year":2020,"finding":"AP-2beta is required for the differentiation of distal tubule precursors into early-stage distal convoluted tubules (DCTs) during nephrogenesis; its downstream target KCTD1 is essential for terminal differentiation of early DCTs into mature DCTs; KCTD1 deficiency leads to severe salt-losing tubulopathy and renal fibrosis by failing to repress beta-catenin activity; AP-2beta/KCTD1 axis links developmental pathway to maintenance of terminal differentiation.","method":"Genetic knockout (conditional), histological analysis, epistasis analysis (AP-2beta→KCTD1→beta-catenin)","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined genetic epistasis with clear pathway placement, multiple KO models, specific cellular phenotypes (DCT differentiation, fibrosis), single rigorous study with multiple orthogonal analyses","pmids":["32553120"],"is_preprint":false},{"year":2016,"finding":"PITX2 is required for expression of Tfap2b in neural crest cells during corneal development; AP-2beta in turn is required for differentiation of corneal endothelium (markers absent in AP-2beta null) and for establishment of angiogenic privilege (blood vessels invade corneal stroma in AP-2beta null), placing AP-2beta downstream of PITX2 in the corneal development pathway.","method":"Conditional knockout (temporal Pitx2 KO and Tfap2b allelic series), microarray, qRT-PCR, in situ hybridization, immunohistochemistry","journal":"Investigative ophthalmology & visual science","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis established with allelic series and conditional KOs, multiple orthogonal readouts, single lab","pmids":["26968737"],"is_preprint":false},{"year":2017,"finding":"TFAP2B mediates noradrenergic neuronal differentiation in neuroblastoma: re-expression of TFAP2B in IMR-32 cells induces neuronal differentiation with upregulation of DBH and TH and downregulation of MYCN and REST; shRNA-mediated knockdown of TFAP2B abrogates retinoic-acid-induced neuronal differentiation of neuroblastoma cells; TFAP2B is silenced by CpG methylation in primary neuroblastomas and demethylation restores expression.","method":"Tetracycline-inducible expression, lentiviral shRNA knockdown, microarray analysis, methylation analysis, 5-aza-2'-deoxycytidine demethylation","journal":"Molecular oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain- and loss-of-function with defined differentiation phenotype, multiple cell lines, single lab","pmids":["26598443"],"is_preprint":false},{"year":2017,"finding":"AP-2beta interacts with beta-catenin both in vitro (GST pull-down) and in vivo (co-immunoprecipitation); the interaction involves the DNA-binding domain of AP-2beta and Armadillo repeats 1–9 of beta-catenin; AP-2beta recruits beta-TrCP and promotes proteasomal degradation of endogenous beta-catenin, thereby inhibiting Wnt/beta-catenin target gene expression and suppressing cervical cancer cell growth in vitro and in vivo.","method":"GST pull-down, co-immunoprecipitation, domain mapping, proteasome inhibitor assay, reporter assay (TCF/LEF), immunohistochemistry, xenograft in vivo assay","journal":"Molecular carcinogenesis","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — reciprocal Co-IP, in vitro pull-down with domain mapping, proteasomal mechanism validated pharmacologically, in vivo functional validation, multiple orthogonal methods, single lab","pmids":["28277615"],"is_preprint":false},{"year":2018,"finding":"TFAP2B directly binds the COX-2 promoter (confirmed by biotin-labeled promoter pulldown and luciferase reporter assays) to activate COX-2 expression; TFAP2B knockdown or overexpression modulates thyroid cancer cell proliferation, apoptosis, invasion, and migration via the COX-2 signaling pathway in vitro and in vivo.","method":"Biotin-labeled promoter pulldown, luciferase reporter assay, siRNA knockdown, overexpression, xenograft mouse model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding assay (pulldown + reporter), gain/loss-of-function with cellular phenotype, single lab","pmids":["31113934"],"is_preprint":false},{"year":2018,"finding":"TFAP2B binds the promoters of COL8A2 and ZP4 genes and transcriptionally regulates their expression in human corneal endothelial cells (CECs); siRNA-mediated knockdown of TFAP2B in CECs decreases COL8A2 and ZP4 expression and suppresses cell proliferation.","method":"siRNA knockdown, reporter gene assay, biochemical (promoter binding) assay, quantitative RT-PCR, immunohistochemistry","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding shown biochemically plus loss-of-function with defined transcriptional and proliferative phenotype, single lab","pmids":["30552118"],"is_preprint":false},{"year":2015,"finding":"In the developing chick limb, AP-2beta expression downstream of FGF signals from the apical ectodermal ridge controls digit morphogenesis; ectopic expression of dominant-negative AP-2beta (equivalent to human Char syndrome mutants) causes reductions in phalange number and length; AP-2beta expression pattern correlates with digit length across amniote species.","method":"Ectopic expression of dominant-negative constructs in chick hindlimb bud, in situ hybridization, comparative expression analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative gain-of-function with defined skeletal phenotype plus in vivo expression-pathway correlation, single lab","pmids":["26277217"],"is_preprint":false},{"year":2017,"finding":"In the developing cerebellum, Tfap2b is selectively expressed by interneurons (not Purkinje cells); in utero electroporation shows Tfap2b is necessary for interneuron specification and capable of suppressing generation of excitatory cells; Tfap2a (but not Tfap2b) can induce interneuron generation when misexpressed in ventricular neuroepithelium.","method":"In utero electroporation (gain- and loss-of-function), immunohistochemistry, genetic mouse analysis","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genetic manipulation via IUE with specific cellular phenotype (interneuron specification), single lab","pmids":["28912684"],"is_preprint":false},{"year":2011,"finding":"AP-2beta interacts with p53 and stabilizes p53 protein; AP-2beta enhances p53-mediated transactivation of the alphaB-crystallin (CRYAB) gene promoter in a p53-dependent manner, as shown by luciferase reporter assay; AP-2beta alone does not activate the CRYAB promoter in the absence of p53.","method":"Luciferase reporter assay, co-immunoprecipitation (interaction with p53), protein stability assay","journal":"Molecular biology reports","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — reporter assay with p53 dependency demonstrated, Co-IP for interaction, single lab, two orthogonal methods","pmids":["21556774"],"is_preprint":false},{"year":2011,"finding":"Postprandial activation of PKCmu positively regulates MCP-1 and IL-6 expression and negatively regulates adiponectin expression via AP-2beta; overexpression of PKCmu enhances the stimulatory and inhibitory effects of AP-2beta on these adipocytokines; PKCmu cannot activate a mutant MCP-1 promoter lacking the AP-2beta binding domain, placing AP-2beta downstream of PKCmu in the postprandial adipocytokine regulatory pathway.","method":"Overexpression, promoter-reporter assay, binding site mutagenesis, signaling pathway analysis in 3T3-L1 adipocytes","journal":"International journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway placement established by promoter mutagenesis and overexpression, single lab","pmids":["21424113"],"is_preprint":false},{"year":2012,"finding":"AP-2beta regulates apolipoprotein E (apoE) transcription in mouse primary astrocytes in response to amyloid-beta42 (Abeta42); Abeta42 increases AP-2beta nuclear levels while reducing AP-2alpha; in cells expressing AP-2 and incubated with Abeta42, the apoE promoter containing AP-2 binding sites shows enhanced activation compared to AP-2-deficient cells.","method":"Primary astrocyte culture, nuclear fractionation, promoter-reporter assay, pharmacological (beta-adrenergic receptor antagonist) experiments","journal":"Brain research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — reporter assay plus fractionation, single lab, indirect evidence of mechanism","pmids":["22325097"],"is_preprint":false},{"year":2018,"finding":"AP-2beta inhibits hepatocellular carcinoma (HCC) cell invasion and metastasis by suppressing EMT through downregulation of Slug and Snail; AP-2beta overexpression reduces HCC proliferation, migration, invasion, and metastasis in vitro and in vivo; oncogenic miR-27a inhibits AP-2beta expression by directly binding its 3' UTR, reversing the tumor-suppressive role.","method":"Overexpression and knockdown, in vitro migration/invasion assays, in vivo mouse experiments, miRNA-3'UTR binding assay","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function with defined pathway (EMT/Slug/Snail) and in vivo validation, single lab","pmids":["30026878"],"is_preprint":false},{"year":2020,"finding":"AP-2beta is required for formation of the trabecular meshwork (TM) and Schlemm's canal (SC) in mouse eyes; conditional deletion of AP-2beta in neural crest cells causes defective POM proliferation in the angle region postnatally, loss of TM and SC marker expression, and elevated intraocular pressure.","method":"Conditional knockout (Wnt1Cre; Tfap2b-/lox), histology, immunohistochemistry, TUNEL assay, ultrastructural analysis, fate mapping","journal":"Experimental eye research","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with defined cellular differentiation phenotype, fate mapping, multiple anatomical/molecular readouts, single rigorous study","pmids":["32353428"],"is_preprint":false},{"year":2022,"finding":"tfap2b disruption in zebrafish (CRISPR/Cas9) leads to decreased enteric neuronal numbers and delayed gastrointestinal transit time; tfap2b crispants show decreased ednrbb mRNA, a downstream target; in vitro studies showed that a human TFAP2B deletion causes loss of exon 4 and absence of TFAP2B protein via premature stop codon.","method":"CRISPR/Cas9 zebrafish model, enteric neuron counting, GI transit assay, in vitro splicing assay, WES","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo CRISPR loss-of-function with defined neuronal and functional phenotype, downstream target identified, single lab","pmids":["35874825"],"is_preprint":false},{"year":2020,"finding":"Tfap2b specifies a melanocyte stem cell (McSC) population at the dorsal root ganglia in zebrafish; Tfap2b is required for McSC-dependent melanocyte regeneration (only a few late-stage embryonic melanocytes require it); fate mapping reveals tfap2b+ McSCs have multifate potential, giving rise to melanocytes, iridophores, xanthophores, and nerve-associated cells.","method":"Genetic loss-of-function, fate mapping, live imaging, clonal analysis in zebrafish","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function and fate mapping with multiple defined cellular phenotypes, replicated across pigment cell lineages in one rigorous study","pmids":["35021087"],"is_preprint":false},{"year":2023,"finding":"Tfap2b acts in postnatal GABAergic neurons to regulate sleep; specific deletion of Tfap2b in GABAergic neurons (Vgat-tfap2b-/-) causes shortened NREM and REM sleep time and reduced delta and theta power under baseline conditions and during rebound sleep; GABAergic gene expression (GAD1, GAD2, Vgat) is downregulated in cortex, brainstem, and cerebellum of Tfap2b+/- mice.","method":"Conditional knockout (Vgat-Cre), EEG/EMG recording, sleep deprivation paradigm, qPCR, RNA-seq","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific conditional KO with quantitative EEG/EMG sleep phenotype, molecular pathway analysis, multiple orthogonal readouts","pmids":["37198238"],"is_preprint":false},{"year":2020,"finding":"Tfap2b heterozygous and intron-mutant mice show altered sleep architecture (increased wakefulness, decreased NREMS, or fragmented NREMS depending on allele); Tfap2b-LacZ expression in adult brain localizes to superior colliculus, locus coeruleus, cerebellum, and nucleus of the solitary tract; embryonic brain TFAP2B protein levels are reduced in splicing mutants.","method":"CRISPR/Cas9-generated mutant mice, EEG/EMG recording, LacZ reporter expression, western blot","journal":"Genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — engineered point mutants mimicking human disease, direct EEG/EMG phenotyping, subcellular localization by reporter, single lab","pmids":["32878901"],"is_preprint":false},{"year":2024,"finding":"TFAP2B in postnatal neurons is required for normal NREM sleep; nervous system-specific deletion of Tfap2b during development causes more severe sleep phenotypes than postnatal neuronal deletion, including defective light entrainment of the circadian clock and stereotypic jumping behavior, indicating TFAP2B functions at multiple stages and/or cell types.","method":"Cre-loxP conditional deletion (nervous system-specific and postnatal neuronal-specific), EEG/EMG recording","journal":"Molecular brain","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO at different developmental stages with EEG phenotype, epistasis by timing, single lab","pmids":["38413970"],"is_preprint":false},{"year":2009,"finding":"AP-2beta overexpression in HIT-T15 insulin-secreting cells inhibits glucose-induced insulin secretion; this is accompanied by decreased Kir6.2 and glucokinase expression; tolbutamide-induced but not KCl-induced secretion is also suppressed, suggesting the effect is upstream of membrane depolarization.","method":"Adenoviral overexpression, insulin secretion assay, western blot/RT-PCR for downstream targets","journal":"Diabetes research and clinical practice","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single overexpression experiment in one cell line with downstream marker analysis, single lab","pmids":["19596470"],"is_preprint":false},{"year":2024,"finding":"TFAP2B directly binds the BNIP3 gene promoter to transcriptionally activate BNIP3 expression in neurons; TFAP2B overexpression in primary neurons reduces apoptosis and enhances pro-survival BNIP3-mediated mitophagy during oxygen-glucose deprivation/reperfusion injury; TFAP2B also reduces MCAO/R damage in vivo.","method":"Overexpression in primary neurons, RNA-seq, promoter binding validation experiments, OGD/R in vitro model, MCAO/R rat model","journal":"Molecular neurobiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, promoter binding validated but full mechanistic detail not specified in abstract, in vivo result described as partial","pmids":["38381297"],"is_preprint":false},{"year":2023,"finding":"Ap-2beta activates Wnt/beta-catenin signaling in osteoblasts; Ap-2beta overexpression increases nuclear beta-catenin and Wnt target gene expression; Ap-2beta knockdown in frontal preosteoblasts reduces proliferation, increases cell death, impairs differentiation, and reduces active beta-catenin; Ap-2beta's osteogenic function cannot be rescued by pharmacological (LiCl) Wnt activation when Ap-2beta itself is absent, suggesting it acts upstream of beta-catenin.","method":"Knockdown, overexpression via lentivirus, luciferase reporter (beta-catenin/TCF/LEF), RNA-seq, pharmacological Wnt activation","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain/loss-of-function with reporter assay and pathway analysis, single lab","pmids":["37355029"],"is_preprint":false},{"year":2024,"finding":"TFAP2B transcriptionally regulates SIRT1 expression to inhibit NF-kappaB activation by reducing acetylation of the p65 subunit, thereby suppressing osteoclast differentiation; TFAP2B overexpression inhibits and knockdown promotes RANKL-induced osteoclast differentiation; TFAP2B and SIRT1 are down-regulated in middle ear cholesteatoma clinical samples.","method":"Overexpression, knockdown, osteoclast differentiation assay (RANKL-induced RAW264.7), western blot, immunohistochemistry, NF-kappaB reporter","journal":"Biochemical and biophysical research communications","confidence":"Low","confidence_rationale":"Tier 3 / Weak — gain/loss-of-function with pathway analysis, single lab, mechanistic detail partially inferred from downstream markers","pmids":["39946982"],"is_preprint":false},{"year":2024,"finding":"Autophagy initiation (via mTORC1 inhibition by rapamycin) enhances p150Glued-AP-2beta complex formation in neurons and non-neuronal cells; this interaction is indirect and requires integrity of the dynactin complex; in non-neuronal cells the interaction also requires CLIP-170, active autophagy, and an intact endolysosomal system; the rapamycin-dependent p150Glued-AP-2beta interaction occurs on LAMP1-positive organelles and correlates with increased speed of retrograde lysosome transport.","method":"Co-immunoprecipitation, rapamycin treatment, siRNA knockdown of CLIP-170/dynactin subunits, live-cell imaging of lysosome transport, LAMP1 colocalization","journal":"Cellular and molecular life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus live imaging with functional transport readout, multiple perturbations, single lab","pmids":["38758395"],"is_preprint":false},{"year":1994,"finding":"AP-2beta was molecularly cloned and shown to encode a functional transcription factor; in situ hybridizations of murine embryo sections revealed tissue-specific and temporally restricted expression in the developing midbrain and in sensory neurons for taste, olfaction, and palpation.","method":"Molecular cloning, in situ hybridization","journal":"Verhandlungen der Deutschen Gesellschaft fur Pathologie","confidence":"Low","confidence_rationale":"Tier 3 / Weak — initial cloning report with expression pattern, functional transcription factor activity inferred from sequence/in vitro, single early paper","pmids":["7534010"],"is_preprint":false},{"year":2025,"finding":"In molecular apocrine (ER-negative, AR-positive) breast cancer cells, AP-2beta occupies active enhancers co-bound by AR, GATA3, and FOXA1; genes defining molecular apocrine identity are significantly more likely to have active enhancers co-occupied by all four transcription factors; when present alone, AP-2beta is preferentially enriched at active promoters; reducing AP-2beta expression potently inhibits proliferation and viability associated with downregulation of MYC oncogene expression.","method":"ChIP-seq for AP-2beta, AR, GATA3, FOXA1, and H3K27ac; siRNA knockdown with proliferation/viability assay","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq with multiple transcription factors plus loss-of-function, preprint not yet peer-reviewed","pmids":["bio_10.1101_2025.07.05.663274"],"is_preprint":true}],"current_model":"TFAP2B encodes a neural-crest-expressed transcription factor that directly binds target gene promoters/enhancers (including Bmp2/4, PNMT, leptin, COX-2, COL8A2, ZP4, BNIP3, and D1A dopamine receptor) to activate or repress transcription; it dimerizes with other AP-2 family members (and with coactivators such as GAS41) to regulate transactivation; disease-causing mutations exert dominant-negative effects by impairing DNA binding while preserving dimerization, or alternatively cause haploinsufficiency via splicing defects; its downstream targets include the AP-2beta/KCTD1 axis controlling distal nephron differentiation, noradrenergic/epinephrine neurotransmitter phenotype specification, GABAergic neuron-dependent NREM sleep, ductus arteriosus closure, corneal endothelium differentiation, trabecular meshwork formation, and cell survival in multiple lineages."},"narrative":{"mechanistic_narrative":"TFAP2B (AP-2beta) is a neural-crest-expressed sequence-specific transcription factor that programs cell survival, differentiation, and lineage identity across multiple developing tissues by binding target promoters and enhancers to activate or repress transcription [PMID:9271117, PMID:7534010]. It functions as a dimer whose DNA-binding basic domain and transactivation PY-motif are separable, and missense mutations that abolish DNA binding (R225C/R225S) or disrupt the PY motif (P62R) while preserving dimerization act dominant-negatively to cause Char syndrome, with intronic splicing mutations producing an alternative haploinsufficiency mechanism [PMID:10802654, PMID:11505339, PMID:15684060]. Its transactivation is modulated by direct protein partners: GAS41 binds the AP-2beta C-terminus to enhance DNA binding and stimulate transcription [PMID:16698963], and AP-2beta interacts with and stabilizes p53 to potentiate p53-dependent target activation [PMID:21556774]. Through direct promoter regulation of survival genes, AP-2beta sustains epithelial and neuronal lineages, exemplified by collecting-duct/distal-tubule survival whose loss produces apoptotic polycystic kidney disease [PMID:9271117] and by survival of sympathetic progenitors and noradrenergic neurons [PMID:21539825]. AP-2beta specifies catecholaminergic neurotransmitter phenotypes by driving DBH, TH and PNMT expression — binding the PNMT promoter directly — to establish noradrenergic and adrenal epinephrine identity [PMID:18424435, PMID:20875861, PMID:26598443]. In organ morphogenesis it directly controls Bmp2/Bmp4 to close the ductus arteriosus and pattern digits [PMID:21829553], lies downstream of PITX2 to differentiate corneal endothelium and form the trabecular meshwork via direct regulation of COL8A2 and ZP4 [PMID:26968737, PMID:30552118, PMID:32353428], and acts through a KCTD1 axis restraining beta-catenin to drive distal convoluted tubule differentiation [PMID:32553120]. In the postnatal nervous system AP-2beta operates in GABAergic neurons to maintain GAD1/GAD2/Vgat expression and normal NREM/REM sleep architecture [PMID:37198238, PMID:32878901, PMID:38413970]. AP-2beta also intersects Wnt signaling bidirectionally — recruiting beta-TrCP to degrade beta-catenin in cervical cancer [PMID:28277615] while activating beta-catenin in osteoblasts [PMID:37355029] — and regulates metabolic and tumor phenotypes through direct targets including leptin, COX-2, and an oncogenic role downstream of PAX3/FKHR [PMID:17525748, PMID:20065963, PMID:31113934].","teleology":[{"year":1994,"claim":"Establishing the gene's molecular identity: cloning showed AP-2beta is a functional transcription factor with tissue-restricted expression in developing midbrain and sensory neurons, framing it as a developmental regulator.","evidence":"Molecular cloning and in situ hybridization in murine embryos","pmids":["7534010"],"confidence":"Low","gaps":["Initial cloning report; transcriptional activity largely inferred","No target genes identified","No loss-of-function phenotype"]},{"year":1997,"claim":"The first knockout answered what AP-2beta does in vivo, revealing it programs epithelial cell survival during embryogenesis rather than acting merely as a differentiation factor.","evidence":"AP-2beta knockout mouse with kidney histology plus in vitro c-myc apoptosis suppression assay","pmids":["9271117"],"confidence":"High","gaps":["Direct survival-gene targets (bcl-XL/bcl-w/bcl-2) not shown to be directly bound","Mechanism of anti-apoptotic action not resolved"]},{"year":2000,"claim":"Linking TFAP2B to human disease and defining its pathogenic mechanism: Char syndrome mutations dimerize normally but fail to bind DNA, establishing a dominant-negative mode.","evidence":"Positional candidacy plus in vitro dimerization, DNA-binding and transactivation assays","pmids":["10802654"],"confidence":"High","gaps":["Domain-resolved structural basis of impaired binding not established","In vivo demonstration of dominant-negative effect absent"]},{"year":2001,"claim":"Extending the mechanism, additional mutants separated DNA-binding-domain (R225C/S) from transactivation-domain (P62R) lesions, both yielding dominant-negative effects and mapping functionally distinct protein regions.","evidence":"DNA-binding and transactivation assays of four mutants in eukaryotic cells","pmids":["11505339"],"confidence":"High","gaps":["Genotype-phenotype correlation across organs not addressed","Endogenous target consequences not measured"]},{"year":2005,"claim":"Identifying an alternative disease mechanism: intronic mutations cause aberrant splicing and NMD-driven haploinsufficiency, showing TFAP2B disease arises by two distinct routes.","evidence":"Biochemical splicing assay in mammalian cells with linkage analysis","pmids":["15684060"],"confidence":"Medium","gaps":["Single lab, two methods","Quantitative protein reduction in patients not measured"]},{"year":2006,"claim":"Defining a transactivation cofactor: GAS41 directly binds the AP-2beta C-terminus and enhances both its DNA binding and transcriptional output.","evidence":"Reciprocal Co-IP, GST pull-down, EMSA, reporter assay, domain mapping","pmids":["16698963"],"confidence":"High","gaps":["In vivo relevance to specific target genes not shown","Generality across AP-2beta-regulated promoters unknown"]},{"year":2008,"claim":"Establishing a core developmental function: AP-2beta specifies the noradrenergic neurotransmitter phenotype, with NA deficiency causally explaining neonatal lethality.","evidence":"Knockout mouse neurochemistry, pharmacological rescue, gain-of-function in neural crest stem cells","pmids":["18424435"],"confidence":"High","gaps":["Direct transcriptional targets driving NA phenotype not all defined","Specificity over other AP-2 family members partial"]},{"year":2010,"claim":"Showing direct promoter control of catecholaminergic identity: AP-2beta directly binds the PNMT promoter in vivo and is required for adrenal epinephrine and secretory vesicle maturation.","evidence":"Knockout mouse, neurochemistry, EM, in vivo ChIP of rat adrenal","pmids":["20875861"],"confidence":"High","gaps":["Cofactor requirements at PNMT promoter unknown","Vesicle-formation defect mechanism not resolved"]},{"year":2011,"claim":"Resolving the Char-syndrome ductus phenotype mechanistically: Tfap2b directly regulates Bmp2/Bmp4 to drive ductus arteriosus closure and digit patterning.","evidence":"Knockout mouse, in situ hybridization, gel-shift and reporter assays","pmids":["21829553"],"confidence":"High","gaps":["How BMP regulation closes the ductus mechanistically not detailed","Direct vs indirect limb effects partly inferred"]},{"year":2011,"claim":"Generalizing the survival role to the nervous system: AP-2beta (with AP-2alpha) maintains sympathetic progenitor and noradrenergic neuron survival.","evidence":"Constitutive and conditional double-knockout mice with TUNEL analysis","pmids":["21539825"],"confidence":"High","gaps":["Pro-survival target genes not identified","Redundancy boundaries with AP-2alpha incompletely mapped"]},{"year":2020,"claim":"Placing AP-2beta in a defined differentiation pathway: it drives distal convoluted tubule differentiation via a KCTD1 axis that restrains beta-catenin.","evidence":"Conditional knockout mice with genetic epistasis (AP-2beta→KCTD1→beta-catenin)","pmids":["32553120"],"confidence":"High","gaps":["Direct binding of AP-2beta to KCTD1 regulatory regions not shown","Relationship to earlier survival phenotype unclear"]},{"year":2016,"claim":"Defining an upstream regulator and ocular role: AP-2beta lies downstream of PITX2 and is required for corneal endothelium differentiation and angiogenic privilege.","evidence":"Conditional KO allelic series, microarray, qRT-PCR, in situ, IHC","pmids":["26968737"],"confidence":"High","gaps":["Direct PITX2-to-Tfap2b regulatory link not biochemically resolved","Corneal target genes identified later"]},{"year":2017,"claim":"Linking AP-2beta to Wnt control in cancer: it binds beta-catenin, recruits beta-TrCP, and promotes its degradation to suppress Wnt targets and tumor growth.","evidence":"GST pull-down, reciprocal Co-IP, domain mapping, proteasome and TCF/LEF reporter assays, xenografts","pmids":["28277615"],"confidence":"High","gaps":["Reconciliation with context-dependent Wnt activation elsewhere unresolved","Endogenous physiological setting beyond cancer cells unclear"]},{"year":2020,"claim":"Extending ocular function: AP-2beta in neural crest is required for trabecular meshwork and Schlemm's canal formation and intraocular pressure homeostasis.","evidence":"Wnt1Cre conditional KO, histology, IHC, TUNEL, fate mapping","pmids":["32353428"],"confidence":"High","gaps":["Direct TM/SC differentiation targets not all defined","Cause of POM proliferation defect not resolved"]},{"year":2022,"claim":"Demonstrating enteric and pigment lineage roles: tfap2b is required for enteric neuron numbers (via ednrbb) and specifies a multipotent melanocyte stem cell population.","evidence":"CRISPR/Cas9 zebrafish, fate mapping, GI transit and neuron-count assays, in vitro splicing","pmids":["35874825","35021087"],"confidence":"High","gaps":["Direct binding to ednrbb not shown","Conservation of stem-cell role in mammals untested"]},{"year":2023,"claim":"Establishing a postnatal physiological role: Tfap2b acts in GABAergic neurons to maintain GABAergic gene expression and normal NREM/REM sleep architecture.","evidence":"Vgat-Cre conditional KO, EEG/EMG, sleep deprivation, qPCR/RNA-seq","pmids":["37198238","32878901","38413970"],"confidence":"High","gaps":["Direct GABAergic gene targets not defined by binding data","Developmental vs postnatal contributions only partly separated"]},{"year":2024,"claim":"Mapping a non-transcriptional cytoplasmic interaction: autophagy induction promotes an indirect, dynactin-dependent p150Glued-AP-2beta complex on lysosomes that speeds retrograde transport.","evidence":"Co-IP, rapamycin treatment, CLIP-170/dynactin siRNA, live-cell lysosome imaging, LAMP1 colocalization","pmids":["38758395"],"confidence":"Medium","gaps":["Functional role of AP-2beta in transport vs bystander binding unclear","Relationship to its nuclear transcriptional function unknown"]},{"year":null,"claim":"It remains unresolved how AP-2beta's context-dependent and opposing activities — Wnt/beta-catenin degradation versus activation, tumor suppression versus PAX3/FKHR-driven oncogenic survival — are mechanistically specified by partner availability and cell type.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking cofactor context to activator vs repressor output","Genome-wide direct binding map across tissues incomplete","Structural basis of partner-dependent switching unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,9,10,13,18,19]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[1,2,9,10,13]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[17,22]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,24]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[36]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[9,10,13,18,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,10,14,15,26,28]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,11,5]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[17,34]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[8,29,21]}],"complexes":[],"partners":["GAS41","CTNNB1","TP53","BTRC","DCTN1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q92481","full_name":"Transcription factor AP-2-beta","aliases":["Activating enhancer-binding protein 2-beta"],"length_aa":460,"mass_kda":50.5,"function":"Sequence-specific DNA-binding protein that interacts with inducible viral and cellular enhancer elements to regulate transcription of selected genes. AP-2 factors bind to the consensus sequence 5'-GCCNNNGGC-3' and activate genes involved in a large spectrum of important biological functions including proper eye, face, body wall, limb and neural tube development. They also suppress a number of genes including MCAM/MUC18, C/EBP alpha and MYC. AP-2-beta appears to be required for normal face and limb development and for proper terminal differentiation and function of renal tubular epithelia","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q92481/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TFAP2B","classification":"Not Classified","n_dependent_lines":16,"n_total_lines":1208,"dependency_fraction":0.013245033112582781},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TFAP2B","total_profiled":1310},"omim":[{"mim_id":"617035","title":"PATENT DUCTUS ARTERIOSUS 2; PDA2","url":"https://www.omim.org/entry/617035"},{"mim_id":"613420","title":"POTASSIUM CHANNEL TETRAMERIZATION DOMAIN-CONTAINING PROTEIN 1; KCTD1","url":"https://www.omim.org/entry/613420"},{"mim_id":"610161","title":"TRANSCRIPTION FACTOR AP2-DELTA; TFAP2D","url":"https://www.omim.org/entry/610161"},{"mim_id":"607411","title":"PATENT DUCTUS ARTERIOSUS 1; PDA1","url":"https://www.omim.org/entry/607411"},{"mim_id":"606061","title":"T-BOX TRANSCRIPTION FACTOR 20; TBX20","url":"https://www.omim.org/entry/606061"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"epididymis","ntpm":31.4},{"tissue":"retina","ntpm":13.7}],"url":"https://www.proteinatlas.org/search/TFAP2B"},"hgnc":{"alias_symbol":["AP2-B","AP-2beta"],"prev_symbol":[]},"alphafold":{"accession":"Q92481","domains":[{"cath_id":"-","chopping":"228-304","consensus_level":"high","plddt":90.5992,"start":228,"end":304},{"cath_id":"-","chopping":"314-437","consensus_level":"high","plddt":94.4558,"start":314,"end":437}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92481","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92481-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92481-F1-predicted_aligned_error_v6.png","plddt_mean":66.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TFAP2B","jax_strain_url":"https://www.jax.org/strain/search?query=TFAP2B"},"sequence":{"accession":"Q92481","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92481.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92481/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92481"}},"corpus_meta":[{"pmid":"9271117","id":"PMC_9271117","title":"Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9271117","citation_count":235,"is_preprint":false},{"pmid":"10802654","id":"PMC_10802654","title":"Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus.","date":"2000","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10802654","citation_count":187,"is_preprint":false},{"pmid":"26672764","id":"PMC_26672764","title":"Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26672764","citation_count":94,"is_preprint":false},{"pmid":"17525748","id":"PMC_17525748","title":"Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17525748","citation_count":83,"is_preprint":false},{"pmid":"16787706","id":"PMC_16787706","title":"Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder.","date":"2006","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/16787706","citation_count":77,"is_preprint":false},{"pmid":"11505339","id":"PMC_11505339","title":"Novel TFAP2B mutations that cause Char syndrome provide a genotype-phenotype correlation.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11505339","citation_count":76,"is_preprint":false},{"pmid":"15684060","id":"PMC_15684060","title":"Syndromic patent ductus arteriosus: evidence for haploinsufficient TFAP2B mutations and identification of a linked sleep disorder.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15684060","citation_count":58,"is_preprint":false},{"pmid":"15940393","id":"PMC_15940393","title":"Genetic variations in the gene encoding TFAP2B are associated with type 2 diabetes mellitus.","date":"2005","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15940393","citation_count":55,"is_preprint":false},{"pmid":"21829553","id":"PMC_21829553","title":"A heart-hand syndrome gene: Tfap2b plays a critical role in the development and remodeling of mouse ductus arteriosus and limb patterning.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21829553","citation_count":43,"is_preprint":false},{"pmid":"21539825","id":"PMC_21539825","title":"The transcription factors AP-2β and AP-2α are required for survival of sympathetic progenitors and differentiated sympathetic neurons.","date":"2011","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/21539825","citation_count":43,"is_preprint":false},{"pmid":"10090146","id":"PMC_10090146","title":"Differential expression of AP-2alpha and AP-2beta in the developing chick retina: repression of R-FABP promoter activity by AP-2.","date":"1999","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/10090146","citation_count":43,"is_preprint":false},{"pmid":"16698963","id":"PMC_16698963","title":"GAS41 interacts with transcription factor AP-2beta and stimulates AP-2beta-mediated transactivation.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16698963","citation_count":39,"is_preprint":false},{"pmid":"10822354","id":"PMC_10822354","title":"A polymorphic region in the human transcription factor AP-2beta gene is associated with specific personality traits.","date":"2000","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/10822354","citation_count":39,"is_preprint":false},{"pmid":"17123722","id":"PMC_17123722","title":"Genes encoding for AP-2beta and the Serotonin Transporter are associated with the Personality Character Spiritual Acceptance.","date":"2006","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/17123722","citation_count":37,"is_preprint":false},{"pmid":"16373417","id":"PMC_16373417","title":"The transcription factor AP-2beta causes cell enlargement and insulin resistance in 3T3-L1 adipocytes.","date":"2005","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16373417","citation_count":35,"is_preprint":false},{"pmid":"21674055","id":"PMC_21674055","title":"Implications of central obesity-related variants in LYPLAL1, NRXN3, MSRA, and TFAP2B on quantitative metabolic traits in adult Danes.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21674055","citation_count":35,"is_preprint":false},{"pmid":"26598443","id":"PMC_26598443","title":"Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.","date":"2015","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/26598443","citation_count":34,"is_preprint":false},{"pmid":"24670271","id":"PMC_24670271","title":"Association study of common polymorphisms in MSRA, TFAP2B, MC4R, NRXN3, PPARGC1A, TMEM18, SEC16B, HOXB5 and OLFM4 genes with obesity-related traits among Portuguese children.","date":"2014","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24670271","citation_count":34,"is_preprint":false},{"pmid":"31113934","id":"PMC_31113934","title":"TFAP2B overexpression contributes to tumor growth and progression of thyroid cancer through the COX-2 signaling pathway.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31113934","citation_count":33,"is_preprint":false},{"pmid":"20703240","id":"PMC_20703240","title":"Polymorphisms in NRXN3, TFAP2B, MSRA, LYPLAL1, FTO and MC4R and their effect on visceral fat area in the Japanese population.","date":"2010","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20703240","citation_count":32,"is_preprint":false},{"pmid":"28912684","id":"PMC_28912684","title":"Distinct Activities of Tfap2A and Tfap2B in the Specification of GABAergic Interneurons in the Developing Cerebellum.","date":"2017","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28912684","citation_count":32,"is_preprint":false},{"pmid":"10984642","id":"PMC_10984642","title":"The genotype of human transcription factor AP-2beta is associated with platelet monoamine oxidase B activity.","date":"2000","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/10984642","citation_count":32,"is_preprint":false},{"pmid":"32553120","id":"PMC_32553120","title":"AP-2β/KCTD1 Control Distal Nephron Differentiation and Protect against Renal Fibrosis.","date":"2020","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/32553120","citation_count":31,"is_preprint":false},{"pmid":"22959235","id":"PMC_22959235","title":"Analyses of GATA4, NKX2.5, and TFAP2B genes in subjects from southern China with sporadic congenital heart disease.","date":"2012","source":"Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22959235","citation_count":31,"is_preprint":false},{"pmid":"18424435","id":"PMC_18424435","title":"Regulation of the noradrenaline neurotransmitter phenotype by the transcription factor AP-2beta.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18424435","citation_count":31,"is_preprint":false},{"pmid":"30026878","id":"PMC_30026878","title":"AP-2β inhibits hepatocellular carcinoma invasion and metastasis through Slug and Snail to suppress epithelial-mesenchymal transition.","date":"2018","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/30026878","citation_count":30,"is_preprint":false},{"pmid":"22952648","id":"PMC_22952648","title":"TFAP2B influences the effect of dietary fat on weight loss under energy restriction.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22952648","citation_count":28,"is_preprint":false},{"pmid":"11684350","id":"PMC_11684350","title":"Levels of transcription factors AP-2alpha and AP-2beta in the brainstem are correlated to monoamine turnover in the rat forebrain.","date":"2001","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/11684350","citation_count":27,"is_preprint":false},{"pmid":"28123844","id":"PMC_28123844","title":"Targeting NF-κB/AP-2β signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells.","date":"2017","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28123844","citation_count":27,"is_preprint":false},{"pmid":"35021087","id":"PMC_35021087","title":"Tfap2b specifies an embryonic melanocyte stem cell that retains adult multifate potential.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/35021087","citation_count":26,"is_preprint":false},{"pmid":"31292255","id":"PMC_31292255","title":"Mutations in TFAP2B and previously unimplicated genes of the BMP, Wnt, and Hedgehog pathways in syndromic craniosynostosis.","date":"2019","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/31292255","citation_count":26,"is_preprint":false},{"pmid":"29035379","id":"PMC_29035379","title":"Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2β.","date":"2017","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29035379","citation_count":26,"is_preprint":false},{"pmid":"26968737","id":"PMC_26968737","title":"AP-2β Is a Downstream Effector of PITX2 Required to Specify Endothelium and Establish Angiogenic Privilege During Corneal Development.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/26968737","citation_count":24,"is_preprint":false},{"pmid":"14673213","id":"PMC_14673213","title":"Transcription factor AP-2beta genotype associated with anxiety-related personality traits in women. A replication study.","date":"2003","source":"Neuropsychobiology","url":"https://pubmed.ncbi.nlm.nih.gov/14673213","citation_count":22,"is_preprint":false},{"pmid":"33720400","id":"PMC_33720400","title":"Transcription factor AP-2beta in development, differentiation and tumorigenesis.","date":"2021","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33720400","citation_count":21,"is_preprint":false},{"pmid":"24081236","id":"PMC_24081236","title":"TFAP2B -dietary protein and glycemic index interactions and weight maintenance after weight loss in the DiOGenes trial.","date":"2013","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/24081236","citation_count":21,"is_preprint":false},{"pmid":"28277615","id":"PMC_28277615","title":"Transcription factor AP-2β suppresses cervical cancer cell proliferation by promoting the degradation of its interaction partner β-catenin.","date":"2017","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28277615","citation_count":21,"is_preprint":false},{"pmid":"18752453","id":"PMC_18752453","title":"Novel TFAP2B mutation in nonsyndromic patent ductus arteriosus.","date":"2008","source":"Genetic testing","url":"https://pubmed.ncbi.nlm.nih.gov/18752453","citation_count":21,"is_preprint":false},{"pmid":"19325541","id":"PMC_19325541","title":"The transcription factor TFAP2B is associated with insulin resistance and adiposity in healthy adolescents.","date":"2009","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/19325541","citation_count":20,"is_preprint":false},{"pmid":"30552118","id":"PMC_30552118","title":"Transcription factor TFAP2B up-regulates human corneal endothelial cell-specific genes during corneal development and maintenance.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30552118","citation_count":19,"is_preprint":false},{"pmid":"21643846","id":"PMC_21643846","title":"Familial nonsyndromic patent ductus arteriosus caused by mutations in TFAP2B.","date":"2011","source":"Pediatric cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/21643846","citation_count":19,"is_preprint":false},{"pmid":"32067207","id":"PMC_32067207","title":"Long non-coding RNA TP73-AS1 promotes TFAP2B-mediated proliferation, metastasis and invasion in retinoblastoma via decoying of miRNA-874-3p.","date":"2020","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/32067207","citation_count":19,"is_preprint":false},{"pmid":"10640692","id":"PMC_10640692","title":"AP-2beta represses D(1A) dopamine receptor gene transcription in neuro2a cells.","date":"1999","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10640692","citation_count":18,"is_preprint":false},{"pmid":"20065963","id":"PMC_20065963","title":"Transcription factor AP-2beta inhibits expression and secretion of leptin, an insulin-sensitizing hormone, in 3T3-L1 adipocytes.","date":"2010","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/20065963","citation_count":18,"is_preprint":false},{"pmid":"37355029","id":"PMC_37355029","title":"Ap-2β regulates cranial osteogenic potential via the activation of Wnt/β-catenin signaling pathway.","date":"2023","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/37355029","citation_count":17,"is_preprint":false},{"pmid":"20019683","id":"PMC_20019683","title":"Relation of the expression of transcriptional factor TFAP2B to that of adipokines in subcutaneous and omental adipose tissues.","date":"2009","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20019683","citation_count":16,"is_preprint":false},{"pmid":"22325097","id":"PMC_22325097","title":"AP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes.","date":"2012","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/22325097","citation_count":15,"is_preprint":false},{"pmid":"20875861","id":"PMC_20875861","title":"Transcription factor AP-2β regulates the neurotransmitter phenotype and maturation of chromaffin cells.","date":"2010","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/20875861","citation_count":15,"is_preprint":false},{"pmid":"15057523","id":"PMC_15057523","title":"Transcription factor AP-2beta genotype, striatal dopamine D2 receptor density and cerebrospinal fluid monoamine metabolite concentrations in humans.","date":"2003","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/15057523","citation_count":14,"is_preprint":false},{"pmid":"26277217","id":"PMC_26277217","title":"AP-2β is a transcriptional regulator for determination of digit length in tetrapods.","date":"2015","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/26277217","citation_count":12,"is_preprint":false},{"pmid":"28381879","id":"PMC_28381879","title":"TFAP2B mutation and dental anomalies.","date":"2017","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28381879","citation_count":11,"is_preprint":false},{"pmid":"35874825","id":"PMC_35874825","title":"TFAP2B Haploinsufficiency Impacts Gastrointestinal Function and Leads to Pediatric Intestinal Pseudo-obstruction.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35874825","citation_count":11,"is_preprint":false},{"pmid":"33460639","id":"PMC_33460639","title":"Anomalous incisor morphology indicates tissue-specific roles for Tfap2a and Tfap2b in tooth development.","date":"2021","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33460639","citation_count":10,"is_preprint":false},{"pmid":"21504541","id":"PMC_21504541","title":"Association between neonatal temperament, SLC6A4, DRD4 and a functional polymorphism located in TFAP2B.","date":"2011","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/21504541","citation_count":10,"is_preprint":false},{"pmid":"29804851","id":"PMC_29804851","title":"Tfap2b mutation in mice results in patent ductus arteriosus and renal malformation.","date":"2018","source":"The Journal of surgical research","url":"https://pubmed.ncbi.nlm.nih.gov/29804851","citation_count":9,"is_preprint":false},{"pmid":"37198238","id":"PMC_37198238","title":"Tfap2b acts in GABAergic neurons to control sleep in mice.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37198238","citation_count":8,"is_preprint":false},{"pmid":"37962045","id":"PMC_37962045","title":"Novel Circular RNA CircUBAP2 Drives Tumor Progression by Regulating the miR-143/TFAP2B Axis in Prostate Cancer.","date":"2024","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/37962045","citation_count":8,"is_preprint":false},{"pmid":"32878901","id":"PMC_32878901","title":"Sleep Architecture in Mice Is Shaped by the Transcription Factor AP-2β.","date":"2020","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32878901","citation_count":8,"is_preprint":false},{"pmid":"32353428","id":"PMC_32353428","title":"AP-2β is required for formation of the murine trabecular meshwork and Schlemm's canal.","date":"2020","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/32353428","citation_count":8,"is_preprint":false},{"pmid":"27984181","id":"PMC_27984181","title":"AP-2α and AP-2β regulate dorsal interneuron specification in the spinal cord.","date":"2016","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27984181","citation_count":7,"is_preprint":false},{"pmid":"38398178","id":"PMC_38398178","title":"ATOH1, TFAP2B, and CEACAM6 as Immunohistochemical Markers to Distinguish Merkel Cell Carcinoma and Small Cell Lung Cancer.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/38398178","citation_count":7,"is_preprint":false},{"pmid":"18358611","id":"PMC_18358611","title":"Electrophysiological and behavioral correlates of polymorphisms in the transcription factor AP-2beta coding gene.","date":"2008","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/18358611","citation_count":7,"is_preprint":false},{"pmid":"28894266","id":"PMC_28894266","title":"Generation of a new mouse model of glaucoma characterized by reduced expression of the AP-2β and AP-2δ proteins.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28894266","citation_count":7,"is_preprint":false},{"pmid":"38381297","id":"PMC_38381297","title":"Transcription Factor TFAP2B Exerts Neuroprotective Effects Targeting BNIP3-Mediated Mitophagy in Ischemia/Reperfusion Injury.","date":"2024","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/38381297","citation_count":6,"is_preprint":false},{"pmid":"33123240","id":"PMC_33123240","title":"miR-142-5p promotes renal cell tumorigenesis by targeting TFAP2B.","date":"2020","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/33123240","citation_count":6,"is_preprint":false},{"pmid":"36076256","id":"PMC_36076256","title":"The regulatory role of AP-2β in monoaminergic neurotransmitter systems: insights on its signalling pathway, linked disorders and theragnostic potential.","date":"2022","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/36076256","citation_count":6,"is_preprint":false},{"pmid":"29715367","id":"PMC_29715367","title":"Conditional Deletion of AP-2α and AP-2β in the Developing Murine Retina Leads to Altered Amacrine Cell Mosaics and Disrupted Visual Function.","date":"2018","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/29715367","citation_count":6,"is_preprint":false},{"pmid":"38758395","id":"PMC_38758395","title":"Autophagy initiation triggers p150Glued-AP-2β interaction on the lysosomes and facilitates their transport.","date":"2024","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/38758395","citation_count":5,"is_preprint":false},{"pmid":"21556774","id":"PMC_21556774","title":"AP-2β enhances p53-mediated transcription of the αB-crystallin gene through stabilizing p53.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21556774","citation_count":5,"is_preprint":false},{"pmid":"34445433","id":"PMC_34445433","title":"Conditional Deletion of AP-2β in the Periocular Mesenchyme of Mice Alters Corneal Epithelial Cell Fate and Stratification.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34445433","citation_count":5,"is_preprint":false},{"pmid":"21424113","id":"PMC_21424113","title":"Postprandial activation of protein kinase Cµ regulates the expression of adipocytokines via the transcription factor AP-2β.","date":"2011","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21424113","citation_count":5,"is_preprint":false},{"pmid":"12270648","id":"PMC_12270648","title":"No association between a transcription factor Activating Protein 2beta (AP-2beta) gene variant and schizophrenia.","date":"2002","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/12270648","citation_count":5,"is_preprint":false},{"pmid":"29683802","id":"PMC_29683802","title":"A study of familial Char syndrome involving the TFAP2B gene with a focus on facial shape characteristics.","date":"2018","source":"Clinical dysmorphology","url":"https://pubmed.ncbi.nlm.nih.gov/29683802","citation_count":5,"is_preprint":false},{"pmid":"38237728","id":"PMC_38237728","title":"AP-2α/AP-2β Transcription Factors Are Key Regulators of Epidermal Homeostasis.","date":"2024","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/38237728","citation_count":4,"is_preprint":false},{"pmid":"31012281","id":"PMC_31012281","title":"A novel missense mutation in TFAP2B associated with Char syndrome and central diabetes insipidus.","date":"2019","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/31012281","citation_count":4,"is_preprint":false},{"pmid":"38069547","id":"PMC_38069547","title":"Generation of tamoxifen-inducible Tfap2b-CreERT2 mice using CRISPR-Cas9.","date":"2023","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/38069547","citation_count":3,"is_preprint":false},{"pmid":"26615960","id":"PMC_26615960","title":"Single nucleotide polymorphisms in AGTR1, TFAP2B, and TRAF1 are not associated with the incidence of patent ductus arteriosus in Japanese preterm infants.","date":"2016","source":"Pediatrics international : official journal of the Japan Pediatric Society","url":"https://pubmed.ncbi.nlm.nih.gov/26615960","citation_count":3,"is_preprint":false},{"pmid":"7534010","id":"PMC_7534010","title":"[Molecular cloning of a new AP-2 transcription factor, AP-2beta, and its function in cell differentiation].","date":"1994","source":"Verhandlungen der Deutschen Gesellschaft fur Pathologie","url":"https://pubmed.ncbi.nlm.nih.gov/7534010","citation_count":3,"is_preprint":false},{"pmid":"39946982","id":"PMC_39946982","title":"TFAP2B governs the regulation of SIRT1 to inhibit osteoclast-induced bone destruction.","date":"2025","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/39946982","citation_count":2,"is_preprint":false},{"pmid":"39052671","id":"PMC_39052671","title":"Transcriptional programs of Pitx2 and Tfap2a/Tfap2b controlling lineage specification of mandibular epithelium during tooth initiation.","date":"2024","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39052671","citation_count":2,"is_preprint":false},{"pmid":"34117603","id":"PMC_34117603","title":"Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18.","date":"2021","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/34117603","citation_count":2,"is_preprint":false},{"pmid":"19596470","id":"PMC_19596470","title":"Transcription factor AP-2beta inhibits glucose-induced insulin secretion in cultured insulin-secreting cell-line.","date":"2009","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/19596470","citation_count":2,"is_preprint":false},{"pmid":"38105942","id":"PMC_38105942","title":"AP-2α/AP-2β transcription factors are key regulators of epidermal homeostasis.","date":"2023","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38105942","citation_count":1,"is_preprint":false},{"pmid":"34822722","id":"PMC_34822722","title":"Deletion of transcription factor AP-2β from the developing murine trabecular meshwork region leads to progressive glaucomatous changes.","date":"2021","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/34822722","citation_count":1,"is_preprint":false},{"pmid":"20690033","id":"PMC_20690033","title":"Does the transcription factor AP-2beta have an impact on the genetic and early environmental influence on ethanol consumption?","date":"2010","source":"Journal of neural transmission (Vienna, Austria : 1996)","url":"https://pubmed.ncbi.nlm.nih.gov/20690033","citation_count":1,"is_preprint":false},{"pmid":"38413970","id":"PMC_38413970","title":"Crucial role of TFAP2B in the nervous system for regulating NREM sleep.","date":"2024","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/38413970","citation_count":0,"is_preprint":false},{"pmid":"39097275","id":"PMC_39097275","title":"[Clinical characteristics and genetic analysis of a child with Char syndrome caused by TFAP2B gene variant].","date":"2024","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/39097275","citation_count":0,"is_preprint":false},{"pmid":"21215182","id":"PMC_21215182","title":"[Mutation of TFAP-2B gene in patients with patent ductus arteriosus].","date":"2010","source":"Zhonghua er ke za zhi = Chinese journal of pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/21215182","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.05.663274","title":"The transcription factor AP-2β defines active enhancers conferring molecular apocrine cell identity in breast cancer","date":"2025-07-09","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.05.663274","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.26.605344","title":"Whole genome sequencing of 76 Mexican Indigenous reveals recent selection signatures linked to pathogens and diet adaptation","date":"2024-07-29","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.26.605344","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.06.622355","title":"Comparative Analysis of Neural Crest Development in the Chick and Mouse","date":"2024-11-06","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.06.622355","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":46787,"output_tokens":9959,"usd":0.144873,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20566,"output_tokens":5167,"usd":0.116002,"stage2_stop_reason":"end_turn"},"total_usd":0.260875,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"AP-2beta knockout mice die postnatally due to polycystic kidney disease caused by massive apoptotic death of collecting duct and distal tubular epithelia; in these mice, bcl-XL, bcl-w, and bcl-2 expression is down-regulated, and transfection of AP-2 into cell lines in vitro strongly suppresses c-myc-induced apoptosis, indicating AP-2beta programs cell survival during embryogenesis.\",\n      \"method\": \"Knockout mouse (loss-of-function), in vitro transfection assay, histological/molecular analysis of kidney development\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with defined cellular phenotype, supported by in vitro transfection assay showing suppression of c-myc-induced apoptosis, replicated across multiple analyses in one rigorous study\",\n      \"pmids\": [\"9271117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Missense mutations in TFAP2B cause Char syndrome; mutant TFAP2B proteins dimerize normally in vitro but show abnormal binding to TFAP2 target sequences, and dimerization of mutants with normal TFAP2B adversely affects transactivation, demonstrating a dominant-negative mechanism for disease pathogenesis.\",\n      \"method\": \"In vitro dimerization assay, DNA-binding assay, transactivation assay in eukaryotic cells, positional candidacy mapping\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal functional assays (dimerization, DNA binding, transactivation) in a single rigorous study establishing dominant-negative mechanism\",\n      \"pmids\": [\"10802654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Four additional TFAP2B mutations cause Char syndrome: two basic-domain mutations (R225C, R225S) abolish DNA binding in vitro; a transactivation-domain PY-motif mutation (P62R) retains DNA binding but shows dominant-negative effects in eukaryotic cells. All four mutants demonstrate dominant-negative effects, consistently implicating this mechanism in Char syndrome etiology.\",\n      \"method\": \"In vitro DNA-binding assay, transactivation assay in eukaryotic cells, mutation analysis\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple mutants analyzed with orthogonal methods (DNA binding + transactivation), replicating and extending the dominant-negative mechanism established in prior work\",\n      \"pmids\": [\"11505339\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Two intronic TFAP2B mutations in Char syndrome families cause aberrant splicing (demonstrated by biochemical studies in mammalian cells), producing frameshift mRNAs subject to nonsense-mediated decay, establishing haploinsufficiency as an alternative mechanism (distinct from dominant-negative) for TFAP2B-associated disease.\",\n      \"method\": \"Biochemical splicing assay in mammalian cells, sequencing, linkage analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical splicing assay plus genetic linkage, single lab, two methods\",\n      \"pmids\": [\"15684060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"GAS41 physically interacts with AP-2beta both in vivo (co-immunoprecipitation) and in vitro (GST pull-down); the two proteins co-localize in the nucleus; interaction maps to C-termini of both proteins; GAS41 stimulates AP-2beta transcriptional activity and enhances its DNA-binding activity as shown by EMSA.\",\n      \"method\": \"Co-immunoprecipitation, GST pull-down, co-localization (nuclear), EMSA, reporter transactivation assay, domain mapping\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP plus in vitro GST pull-down plus EMSA plus functional reporter assay, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"16698963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TFAP2B is a direct transcriptional target of the PAX3/FKHR fusion oncogene in alveolar rhabdomyosarcoma and mediates the anti-apoptotic (survival) function of PAX3/FKHR in these tumor cells, as validated by comparative expression profiling of PAX3/FKHR silencing in vitro and PAX3/FKHR-specific signatures in vivo.\",\n      \"method\": \"siRNA-mediated silencing, comparative expression profiling (in vitro and in vivo), functional anti-apoptosis validation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (siRNA) with defined cellular phenotype (apoptosis) and cross-validated by in vivo expression signatures, single lab\",\n      \"pmids\": [\"17525748\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AP-2beta represses D1A dopamine receptor gene transcription via a specific silencer element (D1AS1) in D1A-negative Neuro2a cells; AP-2beta binds the D1AS1 site (shown by gel supershift with anti-AP-2beta antibody); co-transfection of AP-2beta expression vector represses D1A promoter activity in a D1AS1-dependent manner; decoy oligonucleotides de-repress the promoter.\",\n      \"method\": \"Deletion CAT reporter analysis, gel-shift/supershift assay, co-transfection, decoy oligonucleotide experiment, RT-PCR\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (gel shift, reporter, decoy oligo) in single lab establishing direct transcriptional repression mechanism\",\n      \"pmids\": [\"10640692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"In the developing chick retina, AP-2beta (expressed in amacrine and horizontal cells) represses the R-FABP promoter; cotransfection of AP-2 expression vectors with a CAT reporter construct in primary retinal cultures decreased R-FABP-dependent expression; R-FABP mRNA and AP-2beta show mutually exclusive expression patterns.\",\n      \"method\": \"cDNA cloning, in situ hybridization, co-transfection reporter assay in primary retinal cultures, mutational analysis of AP-2 binding site\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct reporter assay plus in vivo expression pattern, single lab, two orthogonal methods\",\n      \"pmids\": [\"10090146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AP-2beta is required for noradrenaline (NA) neurotransmitter phenotype specification in both peripheral sympathetic ganglia and locus coeruleus; AP-2beta null mice show significantly reduced NA and dopamine beta-hydroxylase levels; pharmacological rescue with NA intermediate during pregnancy significantly rescues neonatal lethality of AP-2beta(-/-) mice, indicating NA deficiency is a main cause of lethality; forced expression of AP-2beta (but not other AP-2 factors) in neural crest stem cells favors their differentiation into NA neurons.\",\n      \"method\": \"Knockout mouse, neurochemical assay (NA/DBH measurement), pharmacological rescue experiment, forced expression in neural crest stem cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO with defined biochemical phenotype, pharmacological rescue establishing causal link, gain-of-function specificity experiment, multiple orthogonal approaches\",\n      \"pmids\": [\"18424435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"AP-2beta is required for the epinephrine neurotransmitter phenotype and maturation of adrenal chromaffin cells; AP-2beta(-/-) mice show reduced DBH and PNMT expression and >80% reduction in adrenal epinephrine; ultrastructural analysis reveals defective large secretory vesicle formation; ChIP assay of rat adrenal gland shows AP-2beta directly binds the PNMT gene upstream promoter in vivo.\",\n      \"method\": \"Knockout mouse, immunohistochemistry, neurochemical assay (EPI/catecholamine measurement), ultrastructural analysis (EM), chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"Molecular and cellular neurosciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — KO with defined biochemical phenotype, ChIP establishing direct promoter binding in vivo, ultrastructural validation, multiple orthogonal methods\",\n      \"pmids\": [\"20875861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tfap2b is expressed throughout ductus arteriosus development; Tfap2b knockout mice fail to close the ductus arteriosus after birth; Tfap2b directly controls Bmp2 and Bmp4 promoter activity (shown by gel-shift assay and reporter assays); loss of Tfap2b alters Bmp2 and Bmp4 expression in limb buds, causing postaxial accessory digits.\",\n      \"method\": \"Knockout mouse, in situ hybridization, histological analysis, gel-shift assay, promoter-reporter transfection assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — KO with two defined phenotypes (PDA, limb), gel shift and reporter assay establishing direct transcriptional regulation of Bmp2/Bmp4, multiple orthogonal methods\",\n      \"pmids\": [\"21829553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AP-2beta and AP-2alpha are required for survival of sympathetic progenitors and differentiated noradrenergic neurons; AP-2beta knockout alone reduces sympathetic ganglion size ~40% via apoptotic death of neural crest progenitors and causes complete absence of locus coeruleus noradrenergic neurons; conditional double knockout of AP-2alpha/AP-2beta in sympathetic progenitors leads to near-complete loss of neurons postnatally.\",\n      \"method\": \"Constitutive and conditional knockout mice, histological/TUNEL analysis, conditional double KO with Cre-lox\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (constitutive and conditional KO) with defined apoptotic cellular phenotype, replicated across cell types\",\n      \"pmids\": [\"21539825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"AP-2beta overexpression in 3T3-L1 adipocytes causes cell enlargement, triglyceride accumulation, and enhanced glucose uptake via PLC and atypical PKCzeta/lambda (but not PI3-K) signaling; AP-2beta also activates Gab1 tyrosine phosphorylation and its association with PLCgamma; AP-2beta overexpression impairs insulin signaling; siRNA knockdown of AP-2beta inhibits glucose uptake.\",\n      \"method\": \"Overexpression and siRNA knockdown in 3T3-L1 adipocytes, pharmacological inhibitor experiments, kinase activity assays, co-immunoprecipitation\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with defined cellular phenotype, pathway dissection with inhibitors, single lab\",\n      \"pmids\": [\"16373417\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"AP-2beta directly inhibits leptin expression in 3T3-L1 adipocytes by binding to the leptin promoter; overexpression decreases leptin promoter activity, mRNA, and protein secretion; knockdown increases leptin expression; EMSA and ChIP confirm specific AP-2beta binding to the leptin promoter (position +34 to +42 relative to TSS); site-directed mutagenesis of this AP-2 binding site abolishes the inhibitory effect.\",\n      \"method\": \"Overexpression, siRNA knockdown, promoter-reporter assay, EMSA, ChIP, site-directed mutagenesis\",\n      \"journal\": \"International journal of obesity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — multiple orthogonal methods including mutagenesis of binding site, ChIP, EMSA, and gain/loss-of-function, single lab\",\n      \"pmids\": [\"20065963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AP-2beta is required for the differentiation of distal tubule precursors into early-stage distal convoluted tubules (DCTs) during nephrogenesis; its downstream target KCTD1 is essential for terminal differentiation of early DCTs into mature DCTs; KCTD1 deficiency leads to severe salt-losing tubulopathy and renal fibrosis by failing to repress beta-catenin activity; AP-2beta/KCTD1 axis links developmental pathway to maintenance of terminal differentiation.\",\n      \"method\": \"Genetic knockout (conditional), histological analysis, epistasis analysis (AP-2beta→KCTD1→beta-catenin)\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined genetic epistasis with clear pathway placement, multiple KO models, specific cellular phenotypes (DCT differentiation, fibrosis), single rigorous study with multiple orthogonal analyses\",\n      \"pmids\": [\"32553120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PITX2 is required for expression of Tfap2b in neural crest cells during corneal development; AP-2beta in turn is required for differentiation of corneal endothelium (markers absent in AP-2beta null) and for establishment of angiogenic privilege (blood vessels invade corneal stroma in AP-2beta null), placing AP-2beta downstream of PITX2 in the corneal development pathway.\",\n      \"method\": \"Conditional knockout (temporal Pitx2 KO and Tfap2b allelic series), microarray, qRT-PCR, in situ hybridization, immunohistochemistry\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis established with allelic series and conditional KOs, multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"26968737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TFAP2B mediates noradrenergic neuronal differentiation in neuroblastoma: re-expression of TFAP2B in IMR-32 cells induces neuronal differentiation with upregulation of DBH and TH and downregulation of MYCN and REST; shRNA-mediated knockdown of TFAP2B abrogates retinoic-acid-induced neuronal differentiation of neuroblastoma cells; TFAP2B is silenced by CpG methylation in primary neuroblastomas and demethylation restores expression.\",\n      \"method\": \"Tetracycline-inducible expression, lentiviral shRNA knockdown, microarray analysis, methylation analysis, 5-aza-2'-deoxycytidine demethylation\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain- and loss-of-function with defined differentiation phenotype, multiple cell lines, single lab\",\n      \"pmids\": [\"26598443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AP-2beta interacts with beta-catenin both in vitro (GST pull-down) and in vivo (co-immunoprecipitation); the interaction involves the DNA-binding domain of AP-2beta and Armadillo repeats 1–9 of beta-catenin; AP-2beta recruits beta-TrCP and promotes proteasomal degradation of endogenous beta-catenin, thereby inhibiting Wnt/beta-catenin target gene expression and suppressing cervical cancer cell growth in vitro and in vivo.\",\n      \"method\": \"GST pull-down, co-immunoprecipitation, domain mapping, proteasome inhibitor assay, reporter assay (TCF/LEF), immunohistochemistry, xenograft in vivo assay\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reciprocal Co-IP, in vitro pull-down with domain mapping, proteasomal mechanism validated pharmacologically, in vivo functional validation, multiple orthogonal methods, single lab\",\n      \"pmids\": [\"28277615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TFAP2B directly binds the COX-2 promoter (confirmed by biotin-labeled promoter pulldown and luciferase reporter assays) to activate COX-2 expression; TFAP2B knockdown or overexpression modulates thyroid cancer cell proliferation, apoptosis, invasion, and migration via the COX-2 signaling pathway in vitro and in vivo.\",\n      \"method\": \"Biotin-labeled promoter pulldown, luciferase reporter assay, siRNA knockdown, overexpression, xenograft mouse model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding assay (pulldown + reporter), gain/loss-of-function with cellular phenotype, single lab\",\n      \"pmids\": [\"31113934\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TFAP2B binds the promoters of COL8A2 and ZP4 genes and transcriptionally regulates their expression in human corneal endothelial cells (CECs); siRNA-mediated knockdown of TFAP2B in CECs decreases COL8A2 and ZP4 expression and suppresses cell proliferation.\",\n      \"method\": \"siRNA knockdown, reporter gene assay, biochemical (promoter binding) assay, quantitative RT-PCR, immunohistochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding shown biochemically plus loss-of-function with defined transcriptional and proliferative phenotype, single lab\",\n      \"pmids\": [\"30552118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In the developing chick limb, AP-2beta expression downstream of FGF signals from the apical ectodermal ridge controls digit morphogenesis; ectopic expression of dominant-negative AP-2beta (equivalent to human Char syndrome mutants) causes reductions in phalange number and length; AP-2beta expression pattern correlates with digit length across amniote species.\",\n      \"method\": \"Ectopic expression of dominant-negative constructs in chick hindlimb bud, in situ hybridization, comparative expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative gain-of-function with defined skeletal phenotype plus in vivo expression-pathway correlation, single lab\",\n      \"pmids\": [\"26277217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In the developing cerebellum, Tfap2b is selectively expressed by interneurons (not Purkinje cells); in utero electroporation shows Tfap2b is necessary for interneuron specification and capable of suppressing generation of excitatory cells; Tfap2a (but not Tfap2b) can induce interneuron generation when misexpressed in ventricular neuroepithelium.\",\n      \"method\": \"In utero electroporation (gain- and loss-of-function), immunohistochemistry, genetic mouse analysis\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genetic manipulation via IUE with specific cellular phenotype (interneuron specification), single lab\",\n      \"pmids\": [\"28912684\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"AP-2beta interacts with p53 and stabilizes p53 protein; AP-2beta enhances p53-mediated transactivation of the alphaB-crystallin (CRYAB) gene promoter in a p53-dependent manner, as shown by luciferase reporter assay; AP-2beta alone does not activate the CRYAB promoter in the absence of p53.\",\n      \"method\": \"Luciferase reporter assay, co-immunoprecipitation (interaction with p53), protein stability assay\",\n      \"journal\": \"Molecular biology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — reporter assay with p53 dependency demonstrated, Co-IP for interaction, single lab, two orthogonal methods\",\n      \"pmids\": [\"21556774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Postprandial activation of PKCmu positively regulates MCP-1 and IL-6 expression and negatively regulates adiponectin expression via AP-2beta; overexpression of PKCmu enhances the stimulatory and inhibitory effects of AP-2beta on these adipocytokines; PKCmu cannot activate a mutant MCP-1 promoter lacking the AP-2beta binding domain, placing AP-2beta downstream of PKCmu in the postprandial adipocytokine regulatory pathway.\",\n      \"method\": \"Overexpression, promoter-reporter assay, binding site mutagenesis, signaling pathway analysis in 3T3-L1 adipocytes\",\n      \"journal\": \"International journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway placement established by promoter mutagenesis and overexpression, single lab\",\n      \"pmids\": [\"21424113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"AP-2beta regulates apolipoprotein E (apoE) transcription in mouse primary astrocytes in response to amyloid-beta42 (Abeta42); Abeta42 increases AP-2beta nuclear levels while reducing AP-2alpha; in cells expressing AP-2 and incubated with Abeta42, the apoE promoter containing AP-2 binding sites shows enhanced activation compared to AP-2-deficient cells.\",\n      \"method\": \"Primary astrocyte culture, nuclear fractionation, promoter-reporter assay, pharmacological (beta-adrenergic receptor antagonist) experiments\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — reporter assay plus fractionation, single lab, indirect evidence of mechanism\",\n      \"pmids\": [\"22325097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AP-2beta inhibits hepatocellular carcinoma (HCC) cell invasion and metastasis by suppressing EMT through downregulation of Slug and Snail; AP-2beta overexpression reduces HCC proliferation, migration, invasion, and metastasis in vitro and in vivo; oncogenic miR-27a inhibits AP-2beta expression by directly binding its 3' UTR, reversing the tumor-suppressive role.\",\n      \"method\": \"Overexpression and knockdown, in vitro migration/invasion assays, in vivo mouse experiments, miRNA-3'UTR binding assay\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function with defined pathway (EMT/Slug/Snail) and in vivo validation, single lab\",\n      \"pmids\": [\"30026878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AP-2beta is required for formation of the trabecular meshwork (TM) and Schlemm's canal (SC) in mouse eyes; conditional deletion of AP-2beta in neural crest cells causes defective POM proliferation in the angle region postnatally, loss of TM and SC marker expression, and elevated intraocular pressure.\",\n      \"method\": \"Conditional knockout (Wnt1Cre; Tfap2b-/lox), histology, immunohistochemistry, TUNEL assay, ultrastructural analysis, fate mapping\",\n      \"journal\": \"Experimental eye research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with defined cellular differentiation phenotype, fate mapping, multiple anatomical/molecular readouts, single rigorous study\",\n      \"pmids\": [\"32353428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"tfap2b disruption in zebrafish (CRISPR/Cas9) leads to decreased enteric neuronal numbers and delayed gastrointestinal transit time; tfap2b crispants show decreased ednrbb mRNA, a downstream target; in vitro studies showed that a human TFAP2B deletion causes loss of exon 4 and absence of TFAP2B protein via premature stop codon.\",\n      \"method\": \"CRISPR/Cas9 zebrafish model, enteric neuron counting, GI transit assay, in vitro splicing assay, WES\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo CRISPR loss-of-function with defined neuronal and functional phenotype, downstream target identified, single lab\",\n      \"pmids\": [\"35874825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tfap2b specifies a melanocyte stem cell (McSC) population at the dorsal root ganglia in zebrafish; Tfap2b is required for McSC-dependent melanocyte regeneration (only a few late-stage embryonic melanocytes require it); fate mapping reveals tfap2b+ McSCs have multifate potential, giving rise to melanocytes, iridophores, xanthophores, and nerve-associated cells.\",\n      \"method\": \"Genetic loss-of-function, fate mapping, live imaging, clonal analysis in zebrafish\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function and fate mapping with multiple defined cellular phenotypes, replicated across pigment cell lineages in one rigorous study\",\n      \"pmids\": [\"35021087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Tfap2b acts in postnatal GABAergic neurons to regulate sleep; specific deletion of Tfap2b in GABAergic neurons (Vgat-tfap2b-/-) causes shortened NREM and REM sleep time and reduced delta and theta power under baseline conditions and during rebound sleep; GABAergic gene expression (GAD1, GAD2, Vgat) is downregulated in cortex, brainstem, and cerebellum of Tfap2b+/- mice.\",\n      \"method\": \"Conditional knockout (Vgat-Cre), EEG/EMG recording, sleep deprivation paradigm, qPCR, RNA-seq\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific conditional KO with quantitative EEG/EMG sleep phenotype, molecular pathway analysis, multiple orthogonal readouts\",\n      \"pmids\": [\"37198238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Tfap2b heterozygous and intron-mutant mice show altered sleep architecture (increased wakefulness, decreased NREMS, or fragmented NREMS depending on allele); Tfap2b-LacZ expression in adult brain localizes to superior colliculus, locus coeruleus, cerebellum, and nucleus of the solitary tract; embryonic brain TFAP2B protein levels are reduced in splicing mutants.\",\n      \"method\": \"CRISPR/Cas9-generated mutant mice, EEG/EMG recording, LacZ reporter expression, western blot\",\n      \"journal\": \"Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — engineered point mutants mimicking human disease, direct EEG/EMG phenotyping, subcellular localization by reporter, single lab\",\n      \"pmids\": [\"32878901\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2B in postnatal neurons is required for normal NREM sleep; nervous system-specific deletion of Tfap2b during development causes more severe sleep phenotypes than postnatal neuronal deletion, including defective light entrainment of the circadian clock and stereotypic jumping behavior, indicating TFAP2B functions at multiple stages and/or cell types.\",\n      \"method\": \"Cre-loxP conditional deletion (nervous system-specific and postnatal neuronal-specific), EEG/EMG recording\",\n      \"journal\": \"Molecular brain\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO at different developmental stages with EEG phenotype, epistasis by timing, single lab\",\n      \"pmids\": [\"38413970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"AP-2beta overexpression in HIT-T15 insulin-secreting cells inhibits glucose-induced insulin secretion; this is accompanied by decreased Kir6.2 and glucokinase expression; tolbutamide-induced but not KCl-induced secretion is also suppressed, suggesting the effect is upstream of membrane depolarization.\",\n      \"method\": \"Adenoviral overexpression, insulin secretion assay, western blot/RT-PCR for downstream targets\",\n      \"journal\": \"Diabetes research and clinical practice\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single overexpression experiment in one cell line with downstream marker analysis, single lab\",\n      \"pmids\": [\"19596470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2B directly binds the BNIP3 gene promoter to transcriptionally activate BNIP3 expression in neurons; TFAP2B overexpression in primary neurons reduces apoptosis and enhances pro-survival BNIP3-mediated mitophagy during oxygen-glucose deprivation/reperfusion injury; TFAP2B also reduces MCAO/R damage in vivo.\",\n      \"method\": \"Overexpression in primary neurons, RNA-seq, promoter binding validation experiments, OGD/R in vitro model, MCAO/R rat model\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, promoter binding validated but full mechanistic detail not specified in abstract, in vivo result described as partial\",\n      \"pmids\": [\"38381297\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Ap-2beta activates Wnt/beta-catenin signaling in osteoblasts; Ap-2beta overexpression increases nuclear beta-catenin and Wnt target gene expression; Ap-2beta knockdown in frontal preosteoblasts reduces proliferation, increases cell death, impairs differentiation, and reduces active beta-catenin; Ap-2beta's osteogenic function cannot be rescued by pharmacological (LiCl) Wnt activation when Ap-2beta itself is absent, suggesting it acts upstream of beta-catenin.\",\n      \"method\": \"Knockdown, overexpression via lentivirus, luciferase reporter (beta-catenin/TCF/LEF), RNA-seq, pharmacological Wnt activation\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain/loss-of-function with reporter assay and pathway analysis, single lab\",\n      \"pmids\": [\"37355029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TFAP2B transcriptionally regulates SIRT1 expression to inhibit NF-kappaB activation by reducing acetylation of the p65 subunit, thereby suppressing osteoclast differentiation; TFAP2B overexpression inhibits and knockdown promotes RANKL-induced osteoclast differentiation; TFAP2B and SIRT1 are down-regulated in middle ear cholesteatoma clinical samples.\",\n      \"method\": \"Overexpression, knockdown, osteoclast differentiation assay (RANKL-induced RAW264.7), western blot, immunohistochemistry, NF-kappaB reporter\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — gain/loss-of-function with pathway analysis, single lab, mechanistic detail partially inferred from downstream markers\",\n      \"pmids\": [\"39946982\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Autophagy initiation (via mTORC1 inhibition by rapamycin) enhances p150Glued-AP-2beta complex formation in neurons and non-neuronal cells; this interaction is indirect and requires integrity of the dynactin complex; in non-neuronal cells the interaction also requires CLIP-170, active autophagy, and an intact endolysosomal system; the rapamycin-dependent p150Glued-AP-2beta interaction occurs on LAMP1-positive organelles and correlates with increased speed of retrograde lysosome transport.\",\n      \"method\": \"Co-immunoprecipitation, rapamycin treatment, siRNA knockdown of CLIP-170/dynactin subunits, live-cell imaging of lysosome transport, LAMP1 colocalization\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus live imaging with functional transport readout, multiple perturbations, single lab\",\n      \"pmids\": [\"38758395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"AP-2beta was molecularly cloned and shown to encode a functional transcription factor; in situ hybridizations of murine embryo sections revealed tissue-specific and temporally restricted expression in the developing midbrain and in sensory neurons for taste, olfaction, and palpation.\",\n      \"method\": \"Molecular cloning, in situ hybridization\",\n      \"journal\": \"Verhandlungen der Deutschen Gesellschaft fur Pathologie\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — initial cloning report with expression pattern, functional transcription factor activity inferred from sequence/in vitro, single early paper\",\n      \"pmids\": [\"7534010\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In molecular apocrine (ER-negative, AR-positive) breast cancer cells, AP-2beta occupies active enhancers co-bound by AR, GATA3, and FOXA1; genes defining molecular apocrine identity are significantly more likely to have active enhancers co-occupied by all four transcription factors; when present alone, AP-2beta is preferentially enriched at active promoters; reducing AP-2beta expression potently inhibits proliferation and viability associated with downregulation of MYC oncogene expression.\",\n      \"method\": \"ChIP-seq for AP-2beta, AR, GATA3, FOXA1, and H3K27ac; siRNA knockdown with proliferation/viability assay\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq with multiple transcription factors plus loss-of-function, preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.07.05.663274\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"TFAP2B encodes a neural-crest-expressed transcription factor that directly binds target gene promoters/enhancers (including Bmp2/4, PNMT, leptin, COX-2, COL8A2, ZP4, BNIP3, and D1A dopamine receptor) to activate or repress transcription; it dimerizes with other AP-2 family members (and with coactivators such as GAS41) to regulate transactivation; disease-causing mutations exert dominant-negative effects by impairing DNA binding while preserving dimerization, or alternatively cause haploinsufficiency via splicing defects; its downstream targets include the AP-2beta/KCTD1 axis controlling distal nephron differentiation, noradrenergic/epinephrine neurotransmitter phenotype specification, GABAergic neuron-dependent NREM sleep, ductus arteriosus closure, corneal endothelium differentiation, trabecular meshwork formation, and cell survival in multiple lineages.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TFAP2B (AP-2beta) is a neural-crest-expressed sequence-specific transcription factor that programs cell survival, differentiation, and lineage identity across multiple developing tissues by binding target promoters and enhancers to activate or repress transcription [#0, #37]. It functions as a dimer whose DNA-binding basic domain and transactivation PY-motif are separable, and missense mutations that abolish DNA binding (R225C/R225S) or disrupt the PY motif (P62R) while preserving dimerization act dominant-negatively to cause Char syndrome, with intronic splicing mutations producing an alternative haploinsufficiency mechanism [#1, #2, #3]. Its transactivation is modulated by direct protein partners: GAS41 binds the AP-2beta C-terminus to enhance DNA binding and stimulate transcription [#4], and AP-2beta interacts with and stabilizes p53 to potentiate p53-dependent target activation [#22]. Through direct promoter regulation of survival genes, AP-2beta sustains epithelial and neuronal lineages, exemplified by collecting-duct/distal-tubule survival whose loss produces apoptotic polycystic kidney disease [#0] and by survival of sympathetic progenitors and noradrenergic neurons [#11]. AP-2beta specifies catecholaminergic neurotransmitter phenotypes by driving DBH, TH and PNMT expression — binding the PNMT promoter directly — to establish noradrenergic and adrenal epinephrine identity [#8, #9, #16]. In organ morphogenesis it directly controls Bmp2/Bmp4 to close the ductus arteriosus and pattern digits [#10], lies downstream of PITX2 to differentiate corneal endothelium and form the trabecular meshwork via direct regulation of COL8A2 and ZP4 [#15, #19, #26], and acts through a KCTD1 axis restraining beta-catenin to drive distal convoluted tubule differentiation [#14]. In the postnatal nervous system AP-2beta operates in GABAergic neurons to maintain GAD1/GAD2/Vgat expression and normal NREM/REM sleep architecture [#29, #30, #31]. AP-2beta also intersects Wnt signaling bidirectionally — recruiting beta-TrCP to degrade beta-catenin in cervical cancer [#17] while activating beta-catenin in osteoblasts [#34] — and regulates metabolic and tumor phenotypes through direct targets including leptin, COX-2, and an oncogenic role downstream of PAX3/FKHR [#5, #13, #18].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing the gene's molecular identity: cloning showed AP-2beta is a functional transcription factor with tissue-restricted expression in developing midbrain and sensory neurons, framing it as a developmental regulator.\",\n      \"evidence\": \"Molecular cloning and in situ hybridization in murine embryos\",\n      \"pmids\": [\"7534010\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Initial cloning report; transcriptional activity largely inferred\", \"No target genes identified\", \"No loss-of-function phenotype\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The first knockout answered what AP-2beta does in vivo, revealing it programs epithelial cell survival during embryogenesis rather than acting merely as a differentiation factor.\",\n      \"evidence\": \"AP-2beta knockout mouse with kidney histology plus in vitro c-myc apoptosis suppression assay\",\n      \"pmids\": [\"9271117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct survival-gene targets (bcl-XL/bcl-w/bcl-2) not shown to be directly bound\", \"Mechanism of anti-apoptotic action not resolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Linking TFAP2B to human disease and defining its pathogenic mechanism: Char syndrome mutations dimerize normally but fail to bind DNA, establishing a dominant-negative mode.\",\n      \"evidence\": \"Positional candidacy plus in vitro dimerization, DNA-binding and transactivation assays\",\n      \"pmids\": [\"10802654\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Domain-resolved structural basis of impaired binding not established\", \"In vivo demonstration of dominant-negative effect absent\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Extending the mechanism, additional mutants separated DNA-binding-domain (R225C/S) from transactivation-domain (P62R) lesions, both yielding dominant-negative effects and mapping functionally distinct protein regions.\",\n      \"evidence\": \"DNA-binding and transactivation assays of four mutants in eukaryotic cells\",\n      \"pmids\": [\"11505339\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genotype-phenotype correlation across organs not addressed\", \"Endogenous target consequences not measured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying an alternative disease mechanism: intronic mutations cause aberrant splicing and NMD-driven haploinsufficiency, showing TFAP2B disease arises by two distinct routes.\",\n      \"evidence\": \"Biochemical splicing assay in mammalian cells with linkage analysis\",\n      \"pmids\": [\"15684060\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, two methods\", \"Quantitative protein reduction in patients not measured\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defining a transactivation cofactor: GAS41 directly binds the AP-2beta C-terminus and enhances both its DNA binding and transcriptional output.\",\n      \"evidence\": \"Reciprocal Co-IP, GST pull-down, EMSA, reporter assay, domain mapping\",\n      \"pmids\": [\"16698963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance to specific target genes not shown\", \"Generality across AP-2beta-regulated promoters unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Establishing a core developmental function: AP-2beta specifies the noradrenergic neurotransmitter phenotype, with NA deficiency causally explaining neonatal lethality.\",\n      \"evidence\": \"Knockout mouse neurochemistry, pharmacological rescue, gain-of-function in neural crest stem cells\",\n      \"pmids\": [\"18424435\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets driving NA phenotype not all defined\", \"Specificity over other AP-2 family members partial\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showing direct promoter control of catecholaminergic identity: AP-2beta directly binds the PNMT promoter in vivo and is required for adrenal epinephrine and secretory vesicle maturation.\",\n      \"evidence\": \"Knockout mouse, neurochemistry, EM, in vivo ChIP of rat adrenal\",\n      \"pmids\": [\"20875861\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cofactor requirements at PNMT promoter unknown\", \"Vesicle-formation defect mechanism not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Resolving the Char-syndrome ductus phenotype mechanistically: Tfap2b directly regulates Bmp2/Bmp4 to drive ductus arteriosus closure and digit patterning.\",\n      \"evidence\": \"Knockout mouse, in situ hybridization, gel-shift and reporter assays\",\n      \"pmids\": [\"21829553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BMP regulation closes the ductus mechanistically not detailed\", \"Direct vs indirect limb effects partly inferred\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Generalizing the survival role to the nervous system: AP-2beta (with AP-2alpha) maintains sympathetic progenitor and noradrenergic neuron survival.\",\n      \"evidence\": \"Constitutive and conditional double-knockout mice with TUNEL analysis\",\n      \"pmids\": [\"21539825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Pro-survival target genes not identified\", \"Redundancy boundaries with AP-2alpha incompletely mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placing AP-2beta in a defined differentiation pathway: it drives distal convoluted tubule differentiation via a KCTD1 axis that restrains beta-catenin.\",\n      \"evidence\": \"Conditional knockout mice with genetic epistasis (AP-2beta→KCTD1→beta-catenin)\",\n      \"pmids\": [\"32553120\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding of AP-2beta to KCTD1 regulatory regions not shown\", \"Relationship to earlier survival phenotype unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining an upstream regulator and ocular role: AP-2beta lies downstream of PITX2 and is required for corneal endothelium differentiation and angiogenic privilege.\",\n      \"evidence\": \"Conditional KO allelic series, microarray, qRT-PCR, in situ, IHC\",\n      \"pmids\": [\"26968737\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PITX2-to-Tfap2b regulatory link not biochemically resolved\", \"Corneal target genes identified later\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linking AP-2beta to Wnt control in cancer: it binds beta-catenin, recruits beta-TrCP, and promotes its degradation to suppress Wnt targets and tumor growth.\",\n      \"evidence\": \"GST pull-down, reciprocal Co-IP, domain mapping, proteasome and TCF/LEF reporter assays, xenografts\",\n      \"pmids\": [\"28277615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with context-dependent Wnt activation elsewhere unresolved\", \"Endogenous physiological setting beyond cancer cells unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extending ocular function: AP-2beta in neural crest is required for trabecular meshwork and Schlemm's canal formation and intraocular pressure homeostasis.\",\n      \"evidence\": \"Wnt1Cre conditional KO, histology, IHC, TUNEL, fate mapping\",\n      \"pmids\": [\"32353428\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct TM/SC differentiation targets not all defined\", \"Cause of POM proliferation defect not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating enteric and pigment lineage roles: tfap2b is required for enteric neuron numbers (via ednrbb) and specifies a multipotent melanocyte stem cell population.\",\n      \"evidence\": \"CRISPR/Cas9 zebrafish, fate mapping, GI transit and neuron-count assays, in vitro splicing\",\n      \"pmids\": [\"35874825\", \"35021087\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding to ednrbb not shown\", \"Conservation of stem-cell role in mammals untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Establishing a postnatal physiological role: Tfap2b acts in GABAergic neurons to maintain GABAergic gene expression and normal NREM/REM sleep architecture.\",\n      \"evidence\": \"Vgat-Cre conditional KO, EEG/EMG, sleep deprivation, qPCR/RNA-seq\",\n      \"pmids\": [\"37198238\", \"32878901\", \"38413970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct GABAergic gene targets not defined by binding data\", \"Developmental vs postnatal contributions only partly separated\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapping a non-transcriptional cytoplasmic interaction: autophagy induction promotes an indirect, dynactin-dependent p150Glued-AP-2beta complex on lysosomes that speeds retrograde transport.\",\n      \"evidence\": \"Co-IP, rapamycin treatment, CLIP-170/dynactin siRNA, live-cell lysosome imaging, LAMP1 colocalization\",\n      \"pmids\": [\"38758395\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of AP-2beta in transport vs bystander binding unclear\", \"Relationship to its nuclear transcriptional function unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how AP-2beta's context-dependent and opposing activities — Wnt/beta-catenin degradation versus activation, tumor suppression versus PAX3/FKHR-driven oncogenic survival — are mechanistically specified by partner availability and cell type.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking cofactor context to activator vs repressor output\", \"Genome-wide direct binding map across tissues incomplete\", \"Structural basis of partner-dependent switching unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 9, 10, 13, 18, 19]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [1, 2, 9, 10, 13]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [17, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 24]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [36]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [9, 10, 13, 18, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 10, 14, 15, 26, 28]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 11, 5]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 34]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [8, 29, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"GAS41\", \"CTNNB1\", \"TP53\", \"BTRC\", \"DCTN1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}